Publications by authors named "Roger S Lo"

65Publications

SPRED1 deletion confers resistance to MAPK inhibition in melanoma.

J Exp Med 2021 Mar;218(3)

Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital and Dana Farber Cancer Institute, Boston, MA.

View Article and Find Full Text PDF
March 2021

Trying for a BRAF Slam Dunk.

Cancer Discov 2020 May;10(5):640-642

Jonsson Comprehensive Cancer Center at the University of California, Los Angeles, Los Angeles, California.

View Article and Find Full Text PDF
May 2020

The great debate at "Immunotherapy Bridge 2018", Naples, November 29th, 2018.

J Immunother Cancer 2019 08 15;7(1):221. Epub 2019 Aug 15.

Department of Medicine, Roswell Park Comprehensive Cancer Center, Developmental Therapeutics, Buffalo, New York, USA.

View Article and Find Full Text PDF
August 2019

Melanoma to Vitiligo: The Melanocyte in Biology & Medicine-Joint Montagna Symposium on the Biology of Skin/PanAmerican Society for Pigment Cell Research Annual Meeting.

J Invest Dermatol 2020 02 23;140(2):269-274. Epub 2019 Jul 23.

Department of Dermatology, Oregon Health & Science University, Portland, Oregon; Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon; Department of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, Oregon. Electronic address:

View Article and Find Full Text PDF
February 2020

High-Speed Live-Cell Interferometry: A New Method for Quantifying Tumor Drug Resistance and Heterogeneity.

Anal Chem 2018 03 13;90(5):3299-3306. Epub 2018 Feb 13.

Department of Physics , Virginia Commonwealth University , Richmond , Virginia 23284 , United States.

View Article and Find Full Text PDF
March 2018

Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma.

Cancer Discov 2018 01 18;8(1):74-93. Epub 2017 Sep 18.

Division of Dermatology, Department of Medicine, University of California, Los Angeles, California.

View Article and Find Full Text PDF
January 2018

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression.

Cell Rep 2017 05;19(6):1189-1201

Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA; Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA 90095, USA; Division of Surgical Oncology, Department of Surgery, UCLA, Los Angeles, CA 90095, USA. Electronic address:

View Article and Find Full Text PDF
May 2017

JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma.

Cell Discov 2016 6;2:16028. Epub 2016 Sep 6.

Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA; Crump Institute for Molecular Imaging, University of California Los Angeles, Los Angeles, CA, USA; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA; California NanoSystems Institute, University of California Los Angeles, Los Angeles, CA, USA.

View Article and Find Full Text PDF
September 2016

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.

N Engl J Med 2016 Sep 13;375(9):819-29. Epub 2016 Jul 13.

From the University of California, Los Angeles (UCLA) (J.M.Z., A.G.-D., D.S.S., H.E.-O., W.H., S.H.-L., D.Y.T., G.A.-R., S.S., L.B., J.S., B.H.M., B.C., K.R., I.P.S., P.J.S., C.P.-S., G.C., E.S., X.K., J.P., B.B.-M., B.C.-A., T.G.G., P.C.T., R.S.L., A.R.), and Jonsson Comprehensive Cancer Center (B.C., B.C.-A., T.G.G., P.C.T., R.S.L., A.R.) - both in Los Angeles; and the Division of Immunology, Netherlands Cancer Institute, Amsterdam (R.M., T.N.M.S.).

View Article and Find Full Text PDF
September 2016

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.

Cell 2016 Mar 17;165(1):35-44. Epub 2016 Mar 17.

Division of Dermatology, Department of Medicine, University of California, Los Angeles, CA 90095-1662, USA; Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90095-1662, USA; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA 90095-1662, USA; David Geffen School of Medicine, University of California, Los Angeles, CA 90095-1662, USA. Electronic address:

View Article and Find Full Text PDF
March 2016

Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance.

Cell 2015 Sep;162(6):1271-85

Division of Dermatology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095-1662, USA; Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA 90095-1662, USA; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA 90095-1662, USA; David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095-1662, USA. Electronic address:

View Article and Find Full Text PDF
September 2015

Vemurafenib resistance reprograms melanoma cells towards glutamine dependence.

J Transl Med 2015 Jul 3;13:210. Epub 2015 Jul 3.

Department of Cancer Biology, Beckman Research Institute of City of Hope Cancer Center, Duarte, CA, 91010, USA.

View Article and Find Full Text PDF
July 2015

Therapy-induced tumour secretomes promote resistance and tumour progression.

Nature 2015 Apr 25;520(7547):368-72. Epub 2015 Mar 25.

Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.

View Article and Find Full Text PDF
April 2015

Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.

Cancer Cell 2015 Feb 15;27(2):240-56. Epub 2015 Jan 15.

Division of Dermatology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA 90095, USA; David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA. Electronic address:

View Article and Find Full Text PDF
February 2015

Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis.

Cancer Discov 2014 Apr 27;4(4):423-33. Epub 2014 Jan 27.

1Molecular Oncology Laboratory, Oncogenic Signaling and Growth Control Program, 2Translational Research Laboratory, Cancer Therapeutics Program, 3Bioinformatics Core Facility, 4The Cancer Signalling Laboratory, Oncogenic Signaling and Growth Control Program, 5Gene Regulation Laboratory, Cancer Therapeutics Program, 6Molecular Imaging and Targeted Therapeutics Laboratory, Cancer Therapeutics Program, 7Department of Cancer Imaging, Peter MacCallum Cancer Centre, East Melbourne; 8Sir Peter MacCallum Department of Oncology, Departments of 9Biochemistry and Molecular Biology, and 10Pathology, University of Melbourne, Parkville; 11Metabolic Remodelling Laboratory, Metabolic Research Unit, School of Medicine, Deakin University, Waurn Ponds; 12Department of Medicine, St Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 13Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead; 14Department of Tissue Pathology & Diagnostic Oncology, Royal Prince Alfred Hospital; 15Discipline of Pathology, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia; 16Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah; and 17Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California.

View Article and Find Full Text PDF
April 2014

COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors.

Mol Oncol 2014 Mar 1;8(2):250-60. Epub 2013 Dec 1.

Department of Medicine (Division of Hematology-Oncology), David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA; Department of Surgery (Division of Surgical-Oncology), David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA; Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA. Electronic address:

View Article and Find Full Text PDF
March 2014

A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.

Cancer Discov 2014 Jan 21;4(1):69-79. Epub 2013 Nov 21.

1The Division of Dermatology, Department of Medicine, 2Division of Surgical Oncology, Department of Surgery, 3Division of Hematology and Oncology, Department of Medicine, 4Jonsson Comprehensive Cancer Center, 5Department of Molecular and Medical Pharmacology, 6David Geffen School of Medicine, University of California, Los Angeles, California; 7Melanoma Institute of Australia, 8Royal Prince Alfred Hospital, 9Westmead Millennium Institute, and 10Westmead Hospital, University of Sydney, New South Wales, Australia.

View Article and Find Full Text PDF
January 2014

Detecting mechanisms of acquired BRAF inhibitor resistance in melanoma.

Methods Mol Biol 2014 ;1102:163-74

Department of Medicine, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.

View Article and Find Full Text PDF
June 2014

Polymer nanofiber-embedded microchips for detection, isolation, and molecular analysis of single circulating melanoma cells.

Angew Chem Int Ed Engl 2013 Mar 21;52(12):3379-83. Epub 2013 Feb 21.

Department of Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging, University of California, Los Angeles, Los Angeles, CA 90095-1770, USA.

View Article and Find Full Text PDF
March 2013

Melanoma prognostics and personalized therapeutics at a crossroad.

Authors:
Roger S Lo

J Invest Dermatol 2013 Feb;133(2):292-5

Department of Medicine, Division of Dermatology, David Geffen School of Medicine, University of California, Jonsson Comprehensive Cancer Center, Los Angeles, California 90095, USA.

View Article and Find Full Text PDF
February 2013

Topical 5-fluorouracil elicits regressions of BRAF inhibitor-induced cutaneous squamous cell carcinoma.

J Invest Dermatol 2013 Jan 16;133(1):274-6. Epub 2012 Aug 16.

Seccio Dermatologia, Departament de Medicina, Hospital Universitari Vall d’Hebron, Universitat Autonomade Barcelona, Spain.

View Article and Find Full Text PDF
January 2013

MDM4 is a key therapeutic target in cutaneous melanoma.

Nat Med 2012 Aug 22;18(8):1239-47. Epub 2012 Jul 22.

Center for the Biology of Disease, Laboratory for Molecular Cancer Biology, Vlaams Instituut voor Biotechnologie (VIB), Leuven, Belgium; Center for Human Genetics, Katholieke Universiteit (KU) Leuven, Leuven, Belgium.

View Article and Find Full Text PDF
August 2012

Receptor tyrosine kinases in cancer escape from BRAF inhibitors.

Authors:
Roger S Lo

Cell Res 2012 Jun 8;22(6):945-7. Epub 2012 May 8.

Division of Dermatology, Department of Medicine, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, 52-121 CHS, 10833 Le Conte Ave, Los Angeles, CA 90095-1750, USA.

View Article and Find Full Text PDF
June 2012

Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.

PLoS One 2011 14;6(12):e28973. Epub 2011 Dec 14.

Department of Medicine, Division of Hematology/Oncology, University of California Los Angeles, Los Angeles, California, United States of America.

View Article and Find Full Text PDF
August 2012

Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition.

Cancer Res 2011 Aug;71(15):5067-74

Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.

View Article and Find Full Text PDF
August 2011

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.

Nature 2010 Dec 24;468(7326):973-7. Epub 2010 Nov 24.

Division of Dermatology/Department of Medicine, UCLA's Jonsson Comprehensive Cancer Center, 52-121 CHS, Los Angeles, California 90095-1750, USA.

View Article and Find Full Text PDF
December 2010

Transforming growth factor-beta activation promotes genetic context-dependent invasion of immortalized melanocytes.

Cancer Res 2008 Jun;68(11):4248-57

Division of Dermatology/Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California, USA.

View Article and Find Full Text PDF
June 2008